CYPH
Cypherpunk Technologies Inc.
There isn't enough reported data to score CYPH yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CYPH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CYPH's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CYPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.5x | $1.95 | — |
| Cheap | 3.7x | $2.09 | +7.4% |
| Fair | 5.4x | $3.00 | +54% |
| Forward | 5.6x | $1.95 | — |
| Expensive | 13x | $7.33 | +276% |
Historical ranges are pointers, not guarantees.
CYPH's PE is 3.5x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CYPH in the historical PE scenario, which offers more potential upside but is not a forecast.
CYPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CYPH to return to profit, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CYPH on the outlook, with more favorable valuation expectations.
CYPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | -37% |
| Q2 2026 | $0.56 | +$2.11 |
| Q1 2026 | -$0.02 | +$1.65 |
| Q4 2025 | $0.07 | +$1.88 |
| Q3 2023 | -$5.72 | -$1.12 |
| Q2 2023 | -$6.51 | -$1.81 |
| Q1 2023 | -$7.10 | -$2.70 |
| Q4 2022 | -$4.80 | -$0.10 |
CYPH has returned to profit: it earned $0.56 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CYPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $375K | 0% |
| Q3 2021 | $375K | 0% |
| Q2 2021 | $375K | 0% |
| Q1 2021 | $375K | 0% |
OSCR has the stronger quarterly revenue trend. Revenue is flat for CYPH versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -2797% | -889 points |
| Q3 2021 | -3237% | -1235 points |
| Q2 2021 | -2567% | -568 points |
| Q1 2021 | -2446% | -744 points |
| Q4 2020 | -1908% | N/A |
| Q3 2020 | -2002% | N/A |
| Q2 2020 | -1999% | N/A |
| Q1 2020 | -1702% | N/A |
CYPH's operating margin was −2797% last quarter, down 889 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CYPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | +$11.8M |
| Q1 2026 | -$3.4M | +$11.1M |
| Q4 2025 | -$6.6M | +$8.9M |
| Q3 2025 | -$8.3M | +$7.3M |
| Q2 2025 | -$14.5M | -$815K |
| Q1 2025 | -$14.5M | +$1M |
| Q4 2024 | -$15.5M | -$5.1M |
| Q3 2024 | -$15.6M | -$5.1M |
CYPH has burned cash in almost every quarter: −$21M over the past year, against −$60M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CYPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +49.2M shares |
| 1 year | +427% | +176M shares |
| 3 years | +1819% | +206M shares |
| 5 years | +2748% | +210M shares |
CYPH has 217M diluted shares, up 427% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CYPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CYPH Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CYPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.7 | Neutral |
| Stochastic | 55.7 | Neutral |
CYPH's weekly RSI is 50 (neutral) and its Stochastic is 56 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CYPH PE vs Healthcare Sector
| Metric | CYPH | Sector median | Relative |
|---|---|---|---|
| PE | 3.5x | 26x | 87% below |
| PE % | 14 | 29 | 15 pts below |
CYPH has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CYPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.91 | 33% below |
| 20 week MA | $1.97 | 1% below |
| 50 week MA | $1.32 | 48% above |
| 100 week MA | $1.06 | 84% above |
| 200 week MA | $2.12 | 8% below |
CYPH's trend is mixed: it's above two of its five weekly moving averages, and 8% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CYPH on trend strength, trading above more of its moving averages.
CYPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.0 | $22.2 | +102% |
| 2021 | $22.2 | $29.5 | +33% |
| 2022 | $29.5 | $4.70 | -84% |
| 2023 | $4.70 | $4.14 | -12% |
| 2024 | $4.14 | $2.95 | -29% |
| 2025 | $2.95 | $1.20 | -59% |
| 2026 YTD | $1.20 | $1.95 | +63% |
CYPH has finished four years in a row lower, and it's up 63% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CYPH on returns for 2026, with the stronger performance.